5-羟色胺受体
参考资料

↑  Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. . Pharmacol. Rev. 1994, 46 (2): 157–203  [2016-04-25]. PMID 7938165. （原始内容存档于2009-04-10）.
↑  Frazer A, Hensler JG. . Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors  (编). . Philadelphia: Lippincott-Raven. 1999: 263–292  [2008-04-11]. ISBN 0-397-51820-X. （原始内容存档于2008-12-01）.
↑  Qi YX, Xia RY, Wu YS, Stanley D, Huang J, Ye GY. . J. Neurochem. 2014, 131: 767–77. PMID 25187179. doi:10.1111/jnc.12940.
↑  Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. . Eur J Pharmacol. 1998, 361 (2–3): 299–309. PMID 9865521. doi:10.1016/S0014-2999(98)00744-4.
↑  Tomkins DM, Higgins GA, Sellers EM. . Psychopharmacology (Berl). 1994, 115 (1–2): 173–9. PMID 7862892. doi:10.1007/BF02244769.
↑  Müller CP, Carey RJ, Huston JP, De Souza Silva MA. . Prog Neurobiol. 2007, 81 (3): 133–78. PMID 17316955. doi:10.1016/j.pneurobio.2007.01.001.
↑  Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP. . Brain Res. 2005, 1034 (1–2): 162–71. PMID 15713268. doi:10.1016/j.brainres.2004.12.012.
1 2  de Boer SF, Koolhaas JM. . Eur J Pharmacol. 2005, 526 (1–3): 125–39. PMID 16310183. doi:10.1016/j.ejphar.2005.09.065.
↑  Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. . Proceedings of the National Academy of Sciences of the United States of America. 1998, 195 (18): 10734–9. PMC 27964 . PMID 9724773. doi:10.1073/pnas.95.18.10734.
↑  Ebenezer IS, Arkle MJ, Tite RM. . Methods Find Exp Clin Pharmacol. 1998, 29 (4): 269–72. PMID 17609739. doi:10.1358/mf.2007.29.4.1075362.
1 2  Wouters W, Tulp MT, Bevan P. . Eur J Pharmacol. 1998, 149 (3): 213–23. PMID 2842163. doi:10.1016/0014-2999(88)90651-6.
1 2  Horiuchi J, McDowall LM, Dampney RA. . Auton Neurosci. 2008, 142 (1–2): 71–6. PMID 18667366. doi:10.1016/j.autneu.2008.06.004.
↑  Nalivaiko E, Ootsuka Y, Blessing WW. . Am J Physiol Regul Integr Comp Physiol. 2005, 289 (2): R596–R604. PMID 15802554. doi:10.1152/ajpregu.00845.2004.
1 2  Lucot JB. . Eur J Pharmacol. 1994, 253 (1–2): 53–60. PMID 8013549. doi:10.1016/0014-2999(94)90756-0.
↑  Winstanley CA, Theobald DE, Dalley JW, Robbins TW. . Neuropsychopharmacology. 2005, 30 (4): 669–682. PMID 15688093. doi:10.1038/sj.npp.1300610.
↑  Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O. . Behav. Brain Res. 2008, 195 (1): 54–77. PMID 18394726. doi:10.1016/j.bbr.2008.02.023.
↑  Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, Ando T, Inoue M, Maeda J, Suzuki K. . Am J Psychiatry. 2003, 160 (2): 334–40. PMID 12562581. doi:10.1176/appi.ajp.160.2.334.
↑  Kennett GA, Dourish CT, Curzon G. . Eur J Pharmacol. 1987, 134 (3): 265–74. PMID 2883013. doi:10.1016/0014-2999(87)90357-8.
↑  Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC. . Pharmacology. 2003, 67 (4): 182–194. PMID 12595749. doi:10.1159/000068404.
1 2  Millan MJ, Perrin-Monneyron S. . Eur J Pharmacol. 1997, 321 (3): 11–3. PMID 9085055. doi:10.1016/S0014-2999(97)00050-2.
↑  Prow MR, Martin KF, Heal DJ. . Eur J Pharmacol. 1996, 317 (1): 21–8. PMID 8982715. doi:10.1016/S0014-2999(96)00693-0.
1 2  Meyer LC, Fuller A, Mitchell D. . American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. February 2006, 290 (2): R405–13. PMID 16166206. doi:10.1152/ajpregu.00440.2005.
1 2  Popova NK, Amstislavskaya TG. . Psychoneuroendocrinology. 2002, 27 (5): 609–18. PMID 11965359. doi:10.1016/S0306-4530(01)00097-X.
↑  Monti JM, Jantos H. . J Sleep Res. 1992, 1 (3): 169–175. PMID 10607047. doi:10.1111/j.1365-2869.1992.tb00033.x.
↑  Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. . Neuroscience. 2007, 146 (2): 509–14. PMID 17383105. doi:10.1016/j.neuroscience.2007.02.032.
↑  Gudelsky GA, Koenig JI, Meltzer HY. . Neuropharmacology. 1986, 25 (12): 1307–13. PMID 2951611. doi:10.1016/0028-3908(86)90101-2.
↑  Ootsuka Y, Blessing WW. . Brain Res. 2006,. 1073-1074: 252–61. PMID 16455061. doi:10.1016/j.brainres.2005.12.031.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  Pharmacology Corner > Serotonin (5-HT): receptors, agonists and antagonists （页面存档备份，存于） By Flavio Guzmán, M.D. on 9/08/09
1 2 3 4 5  "BRINTELLIX™ (vortioxetine) tablets for oral use. Full Prescribing Information, Section 12.2 (Pharmacodynamics)." Takeda Pharmaceuticals America Inc. and Lundbeck, 2013. Revised September 2013.  （页面存档备份，存于）
↑  Saxena, PR; Lawang, A. . Archives Internationales de Pharmacodynamie et de Thérapie. Oct 1985, 277 (2): 235–52. PMID 2933009.
↑  Cao BJ, Rodgers RJ. . Psychopharmacology. October 1998, 139 (3): 185–94. PMID 9784072. doi:10.1007/s002130050703.
↑  Harrison AA, Parsons LH, Koob GF, Markou A. . Psychopharmacology (Berl). 1999, 141 (3): 242–50. PMID 10027505. doi:10.1007/s002130050831.
↑  Chojnacka-Wójcik E, Klodzinska A, Tatarczynska E. . J Pharm Pharmacol. 2005, 57 (2): 253–7. PMID 15720791. doi:10.1211/0022357055399.
↑  Lin D, Parsons LH. . Pharmacol Biochem Behav. 2002, 71 (4): 581–7. PMID 11888549. doi:10.1016/S0091-3057(01)00712-2.
1 2  Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wójcik E. . Behav Pharmacol. 2004, 15 (8): 523–34. PMID 15577451. doi:10.1097/00008877-200412000-00001.
1 2  Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO. . Neuropharmacology. 2008, 54 (7): 1041–50. PMID 18394658. doi:10.1016/j.neuropharm.2008.02.007.
1 2  McCreary AC, Bankson MG, Cunningham KA. . J Pharmacol Exp Ther. 1999, 290 (3): 965–73. PMID 10454466.
↑  Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J. . Eur Neuropsychopharmacol. 2005, 15 (3): 279–82. PMID 15820416. doi:10.1016/j.euroneuro.2004.12.002.
↑  Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB. . Neurosci Lett. 1996, 209 (3): 210–4. PMID 8736648. doi:10.1016/0304-3940(96)12637-9.
1 2   （页面存档备份，存于） Bubar MJ, Cunningham KA. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem. 2006;6(18):1971-85.
↑  Schreiber R, Melon C, De Vry J. . Psychopharmacology (Berl). 1998, 135 (4): 383–91. PMID 9539263. doi:10.1007/s002130050526.
1 2  Popova NK, Amstislavskaya TG. . Neuroendocrinology. 2002, 76 (1): 28–34. PMID 12097814. doi:10.1159/000063681.
1 2  Popa D, Léna C, Fabre V, Prenat C, Gingrich J, Escourrou P, Hamon M, Adrien J. . J Neurosci. 2005, 25 (49): 11231–8. PMID 16339018. doi:10.1523/JNEUROSCI.1724-05.2005.
1 2  Mazzola-Pomietto P, Aulakh CS, Tolliver T, Murphy DL. . Psychopharmacology (Berl). 1997, 130 (2): 144–51. PMID 9106912. doi:10.1007/s002130050222.
↑  Blessing WW, Seaman B. . Neuroscience. 2003, 117 (4): 939–948. PMID 12654345. doi:10.1016/S0306-4522(02)00810-2.
1 2 3  McCall, R. B.; Franklin, S. R.; Hyslop, D. K.; Knauer, C. S.; Chio, C. L.; Haber, C. L.; Fitzgerald, L. W.  (Online) 27 (309.2). Presentation Number 309.2. Convention Center Exhibit Hall, Poster Board TT-45, San Diego, CA: Society for Neuroscience Abstracts. 2001  [18 July 2014]. （原始内容存档于2014-11-04）.  |conference=被忽略 (帮助)
1 2 3  Garfield AS, Heisler LK. . The Journal of Physiology. 2009, 587 (1): 49–60. PMC 2670022 . PMID 19029184. doi:10.1113/jphysiol.2008.164152.
1 2 3  Jensen, Anders A.; Plath, Niels; Pedersen, Martin Holst Friborg; Isberg, Vignir;  et al. . Journal of Medicinal Chemistry. 2013, 56 (3): 1211–1227. ISSN 0022-2623. doi:10.1021/jm301656h.
↑  Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP. . Br J Pharmacol. 1996, 117 (7): 1443–8. PMC 1909458 . PMID 8730737. doi:10.1111/j.1476-5381.1996.tb15304.x.
↑  Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC. . Neuropharmacology. 1997, 36 (4–5): 601–8. PMID 9225285. doi:10.1016/S0028-3908(97)00042-7.
↑  Kennett GA, Trail B, Bright F. . Neuropharmacology. 1998, 37 (12): 1603–10. PMID 9886683. doi:10.1016/S0028-3908(98)00115-4.
↑  Kennett GA, Ainsworth K, Trail B, Blackburn TP. . Neuropharmacology. 1997, 36 (2): 233–9. PMID 9144661. doi:10.1016/S0028-3908(96)00171-2.
↑  Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS. . Br J Pharmacol. 2002, 135 (5): 1144–1151. PMC 1573235 . PMID 11877320. doi:10.1038/sj.bjp.0704571.
↑  Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP. . Neuropharmacology. 1997, 36 (4–5): 609–20. PMID 9225286. doi:10.1016/S0028-3908(97)00038-5.
1 2  Millan MJ, Brocco M, Gobert A, Dekeyne A. . Psychopharmacology (Berl). 2005, 177 (4): 448–58. PMID 15289999. doi:10.1007/s00213-004-1962-z.
1 2  Millan MJ, Brocco M, Gobert A, Dekeyne A. . Psychopharmacology (Berl). 2008, 199 (4): 549–68. PMID 18523738. doi:10.1007/s00213-008-1177-9.
↑  Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, Fujimiya M, Inui A. . Biol Psychiatry. 2009, 65 (9): 748–759. PMID 19058784. doi:10.1016/j.biopsych.2008.10.031.
↑  Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S. . Eur J Pharmacol. 1997, 325 (1): 9–12. PMID 9151932. doi:10.1016/S0014-2999(97)89962-1.
↑  Stancampiano R, Melis MR, Argiolas A. . Eur J Pharmacol. 1994, 261 (1–2): 149–55. PMID 8001637. doi:10.1016/0014-2999(94)90313-1.
↑  Frank MG, Stryker MP, Tecott LH. . Neuropsychopharmacology. 2002, 27 (5): 869–73. PMC 2452994 . PMID 12431861. doi:10.1016/S0893-133X(02)00353-6.
↑  Rang, H. P. . Edinburgh: Churchill Livingstone. 2003. ISBN 0-443-07145-4.  Page 187
↑  Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, Brady CA, Barnes NM, Schemann M. . National Center for Biotechnology Information. May 2005  [10 October 2014]. （原始内容存档于2016-09-23）.
1 2  Pitsikas N, Brambilla A, Borsini F. . Pharmacol Biochem Behav. 1994, 47 (1): 95–99. PMID 8115433. doi:10.1016/0091-3057(94)90116-3.
1 2  Smriga M, Torii K. . Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (26): 15370–5. PMC 307574 . PMID 14676321. doi:10.1073/pnas.2436556100.
↑  Kennett GA, Bright F, Trail B, Blackburn TP, Sanger GJ. . Neuropharmacology. 1997, 36 (4–5): 707–12. PMID 9225297. doi:10.1016/S0028-3908(97)00037-3.
↑  Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, Charnay Y, Bockaert J, Compan V. . Proceedings of the National Academy of Sciences of the United States of America. 2007, 104 (41): 16335–40. PMC 2042207 . PMID 17913892. doi:10.1073/pnas.0701471104.
↑  J Soc Biol.; Charnay, Y; Dusticier, N; Daszuta, A; Hen, R; Bockaert, J. . J Soc Biol. 2004, 198 (1): 37–49. PMID 15146954.
1 2  Meneses A, Hong E. . Pharmacol Biochem Behav. 1997, 56 (3): 347–51. PMID 9077568. doi:10.1016/S0091-3057(96)00224-9.
1 2  Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM. . Neuropharmacology. 1997, 36 (4–5): 689–96. PMID 9225295. doi:10.1016/S0028-3908(97)00055-5.
↑  Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM. . J Pharmacol Exp Ther. 1998, 286 (3): 1115–21. PMID 9732367.
↑  Lucas, G.; Rymar, V. V.; Du, J.; Mnie-Filali, O.; Bisgaard, C.; Manta, S.; Lambas-Senas, L.; Wiborg, O.; Haddjeri, N.; Piñeyro, G.; Sadikot, A. F.; Debonnel, G. . Neuron. 2007, 55 (5): 712–725. PMID 17785179. doi:10.1016/j.neuron.2007.07.041.
↑  Duman, R. S. . Neuron. 2007, 55 (5): 679–681. PMID 17785173. doi:10.1016/j.neuron.2007.08.011.
↑  Manzke, T. . Science. 2003, 301 (5630): 226–229. ISSN 0036-8075. PMID 12855812. doi:10.1126/science.1084674.
↑  Nelson DL. . Curr Drug Targets CNS Neurol Disord. 2004, 3 (1): 53–8. PMID 14965244. doi:10.2174/1568007043482606.
1 2  Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. . Brain Res Mol Brain Res. 2005, 138 (2): 191–7. PMID 15921820. doi:10.1016/j.molbrainres.2005.04.009.
↑  Zhang, Shicheng; Chen, He; Zhang, Chengwei; Yang, Ying; Popov, Petr; Liu, Jing; Krumm, Brian E.; Cao, Can; Kim, Kuglae; Xiong, Yan; Katritch, Vsevolod. . Nature Structural & Molecular Biology. 2022-07, 29 (7)  [2022-10-02]. ISSN 1545-9993. PMC 9299520 . PMID 35835867. doi:10.1038/s41594-022-00796-6. （原始内容存档于2022-10-06） （英语）.
↑  Wesolowska A. . European Journal of Pharmacology. February 2008, 580 (3): 355–60. PMID 18096153. doi:10.1016/j.ejphar.2007.11.022.
1 2  Wesolowska A, Nikiforuk A. . Neuropharmacology. April 2007, 52 (5): 1274–83. PMID 17320917. doi:10.1016/j.neuropharm.2007.01.007.
↑  Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N. . European Journal of Pharmacology. December 2006, 553 (1–3): 109–19. PMID 17069795. doi:10.1016/j.ejphar.2006.09.049.
1 2  Perez-García G, Meneses A. . Pharmacology, Biochemistry, and Behavior. July 2005, 81 (3): 673–82. PMID 15964617. doi:10.1016/j.pbb.2005.05.005.
↑  Wesolowska A, Nikiforuk A. . European Journal of Pharmacology. March 2008, 582 (1–3): 88–93. PMID 18234190. doi:10.1016/j.ejphar.2007.12.013.
↑  . The Association of the British Pharmaceutical Industry.   [2008-04-11]. （原始内容存档于2008-06-12）.
1 2 3  Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. . Biological Psychiatry. November 2005, 58 (10): 831–7. PMID 16018977. doi:10.1016/j.biopsych.2005.05.012.
1 2  Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. . Neuropharmacology. September 2006, 51 (3): 578–86. PMID 16828124. doi:10.1016/j.neuropharm.2006.04.017.
↑  Gasbarri A, Cifariello A, Pompili A, Meneses A. . Behavioural Brain Research. December 2008, 195 (1): 164–70. PMID 18308404. doi:10.1016/j.bbr.2007.12.020.
↑  Liy-Salmeron G, Meneses A. . Hippocampus. 2008, 18 (9): 965–74. PMID 18570192. doi:10.1002/hipo.20459.
1 2  Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, Miller K, Atack J, Lovenberg TW, Dugovic C. . J Pharmacol Exp Ther. 2007, 321 (2): 690–8. PMID 17314195. doi:10.1124/jpet.107.119404.
↑  Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT. . Br J Pharmacol. 2003, 139 (4): 705–14. PMC 1573887 . PMID 12812993. doi:10.1038/sj.bjp.0705290.
↑  Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf （页面存档备份，存于）